Bram Vanparys, Gimv managing partner, head of life sciences
June 15, 2022 07:41 AM EDTUpdated 04:06 PM
Financing

Long-time health­care in­vestor looks to dou­ble num­ber of life sci­ences star­tups in its 'ev­er­green' fund

Amber Tong

Hav­ing con­sis­tent­ly kept about a dozen life sci­ences com­pa­nies in its port­fo­lio over the past few decades, Eu­ro­pean in­vestor Gimv is ready to dou­ble down …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times